Ignite Creation Date:
2025-12-25 @ 2:42 AM
Ignite Modification Date:
2025-12-31 @ 2:31 PM
Study NCT ID:
NCT00364533
Status:
TERMINATED
Last Update Posted:
2014-04-21
First Post:
2006-08-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Australia', 'Czechia', 'Estonia', 'France', 'Hungary', 'Latvia', 'Lithuania', 'Poland', 'Portugal', 'Romania', 'Slovakia']}, 'conditionBrowseModule': {'meshes': [{'id': 'D018771', 'term': 'Arthralgia'}, {'id': 'D010146', 'term': 'Pain'}], 'ancestors': [{'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}, {'id': 'D012816', 'term': 'Signs and Symptoms'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000077432', 'term': 'Tapentadol'}], 'ancestors': [{'id': 'D010636', 'term': 'Phenols'}, {'id': 'D001555', 'term': 'Benzene Derivatives'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D009930', 'term': 'Organic Chemicals'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'phone': '609-730-6780', 'title': 'Senior Director, Clinical Leader', 'organization': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'}, 'certainAgreement': {'otherDetails': 'A provision provides for 60 day prior review by sponsor extendable by 60 days to file a patent application and prior written consent of sponsor for disclosure of confidential information, if any.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'Sponsor terminated study, sample size not reached. The protocol section describes 4 study arms defining the treatment groups in the study design. The participant flow module describes the 5 treatment groups analyzed for the primary endpoint'}}, 'adverseEventsModule': {'timeFrame': 'All adverse events were reported from the time a signed and dated informed consent was obtained throughout the follow-up phase of the study. Serious adverse events were collected for 30 days after the last dose of study drug.', 'eventGroups': [{'id': 'EG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days', 'otherNumAtRisk': 77, 'otherNumAffected': 52, 'seriousNumAtRisk': 77, 'seriousNumAffected': 1}, {'id': 'EG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days', 'otherNumAtRisk': 71, 'otherNumAffected': 38, 'seriousNumAtRisk': 71, 'seriousNumAffected': 1}, {'id': 'EG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days', 'otherNumAtRisk': 75, 'otherNumAffected': 53, 'seriousNumAtRisk': 75, 'seriousNumAffected': 3}, {'id': 'EG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days', 'otherNumAtRisk': 67, 'otherNumAffected': 43, 'seriousNumAtRisk': 67, 'seriousNumAffected': 1}, {'id': 'EG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days', 'otherNumAtRisk': 75, 'otherNumAffected': 44, 'seriousNumAtRisk': 75, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Anaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 11}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 7}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Body Temperature Increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 8}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 5}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 7}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Confusional State', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 11}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 10}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 7}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Dizziness', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 7}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 16}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 14}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 4}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Dry Mouth', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Hallucination, Visual', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 8}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 2}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 9}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 13}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Hypotension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 2}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Insomnia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 4}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Muscle Spasms', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 1}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 19}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 12}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 12}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 11}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Pruritus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 4}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Skin and subcutaneous tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 15}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 13}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 14}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 7}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Somnolence', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 11}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 10}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 17}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 6}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 10}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 12}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}], 'seriousEvents': [{'term': 'Atrial Fibrillation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Chronic Obstructive Pulmonary Disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Confusional State', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Psychiatric disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Deep Vein Thrombosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Ileus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Lethargy', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Pulmonary Embolism', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}, {'term': 'Supraventricular Tachycardia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 77, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 71, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 75, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 67, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 75, 'numAffected': 0}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 10.1'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Sum of Pain Intensity Difference Over 48 Hours (SPID48)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '35', 'groupId': 'OG000'}, {'value': '31', 'groupId': 'OG001'}, {'value': '30', 'groupId': 'OG002'}, {'value': '36', 'groupId': 'OG003'}, {'value': '24', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days'}], 'classes': [{'categories': [{'measurements': [{'value': '73.9', 'spread': '123.89', 'groupId': 'OG000'}, {'value': '54.4', 'spread': '128.22', 'groupId': 'OG001'}, {'value': '49.3', 'spread': '136.92', 'groupId': 'OG002'}, {'value': '57.6', 'spread': '125.73', 'groupId': 'OG003'}, {'value': '-18.6', 'spread': '130.74', 'groupId': 'OG004'}]}]}], 'analyses': [{'pValue': '<0.001', 'groupIds': ['OG000', 'OG004'], 'paramType': 'LS mean difference of SPID48', 'ciPctValue': '95', 'paramValue': '91.4', 'ciLowerLimit': '49.77', 'ciUpperLimit': '133.07', 'groupDescription': 'The study was terminated and did not reach the planned sample size.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '<0.001', 'groupIds': ['OG001', 'OG004'], 'paramType': 'LS mean difference of SPID48', 'ciPctValue': '95', 'paramValue': '81.5', 'ciLowerLimit': '38.66', 'ciUpperLimit': '124.29', 'groupDescription': 'The study was terminated and did not reach the planned sample size.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '<0.001', 'groupIds': ['OG002', 'OG004'], 'paramType': 'LS mean difference of SPID48', 'ciPctValue': '95', 'paramValue': '81.5', 'ciLowerLimit': '39.21', 'ciUpperLimit': '123.80', 'groupDescription': 'The study was terminated and did not reach the planned sample size.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}, {'pValue': '<0.001', 'groupIds': ['OG003', 'OG004'], 'paramType': 'LS mean difference of SPID48', 'ciPctValue': '95', 'paramValue': '82.4', 'ciLowerLimit': '38.96', 'ciUpperLimit': '125.88', 'groupDescription': 'The study was terminated and did not reach the planned sample size.', 'statisticalMethod': 'ANCOVA', 'nonInferiorityType': 'SUPERIORITY_OR_OTHER', 'testedNonInferiority': False}], 'paramType': 'MEAN', 'timeFrame': '48 hours', 'description': 'The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Because the Sponsor terminated the study, the planned sample size was not reached in any treatment group, therefore, only a brief summary of an exploratory analysis of the primary efficacy variable (SPID48) is presented.'}, {'type': 'SECONDARY', 'title': 'Time to First Rescue Pain Medication.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days'}], 'timeFrame': '3 days', 'reportingStatus': 'POSTED', 'populationDescription': 'Due to termination of trial, results were not analyzed.'}, {'type': 'SECONDARY', 'title': 'The SPID at 12, 24, and 72 Hours Relative to First Dose.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}]}], 'groups': [{'id': 'OG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days'}, {'id': 'OG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days'}], 'timeFrame': '3 days', 'description': 'The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.', 'reportingStatus': 'POSTED', 'populationDescription': 'Due to termination of trial, results were not analyzed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'FG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'FG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'FG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days'}, {'id': 'FG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '77'}, {'groupId': 'FG001', 'numSubjects': '71'}, {'groupId': 'FG002', 'numSubjects': '75'}, {'groupId': 'FG003', 'numSubjects': '67'}, {'groupId': 'FG004', 'numSubjects': '75'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '35'}, {'groupId': 'FG001', 'numSubjects': '31'}, {'groupId': 'FG002', 'numSubjects': '30'}, {'groupId': 'FG003', 'numSubjects': '36'}, {'groupId': 'FG004', 'numSubjects': '24'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '42'}, {'groupId': 'FG001', 'numSubjects': '40'}, {'groupId': 'FG002', 'numSubjects': '45'}, {'groupId': 'FG003', 'numSubjects': '31'}, {'groupId': 'FG004', 'numSubjects': '51'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}, {'groupId': 'FG001', 'numSubjects': '7'}, {'groupId': 'FG002', 'numSubjects': '15'}, {'groupId': 'FG003', 'numSubjects': '5'}, {'groupId': 'FG004', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '8'}, {'groupId': 'FG002', 'numSubjects': '6'}, {'groupId': 'FG003', 'numSubjects': '6'}, {'groupId': 'FG004', 'numSubjects': '6'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '22'}, {'groupId': 'FG001', 'numSubjects': '22'}, {'groupId': 'FG002', 'numSubjects': '21'}, {'groupId': 'FG003', 'numSubjects': '17'}, {'groupId': 'FG004', 'numSubjects': '42'}]}, {'type': 'Subject discharged from hospital', 'reasons': [{'groupId': 'FG000', 'numSubjects': '4'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '1'}]}, {'type': 'Variations in drug compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Non-compliance', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '77', 'groupId': 'BG000'}, {'value': '71', 'groupId': 'BG001'}, {'value': '75', 'groupId': 'BG002'}, {'value': '67', 'groupId': 'BG003'}, {'value': '75', 'groupId': 'BG004'}, {'value': '365', 'groupId': 'BG005'}]}], 'groups': [{'id': 'BG000', 'title': 'Tapentadol IR Fixed Dose 50 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'BG001', 'title': 'Tapentadol IR Fixed Dose 75 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'BG002', 'title': 'Tapentadol IR Fixed Dose 100 mg', 'description': 'Tapentadol taken by mouth every 4-6 hours for 3 days'}, {'id': 'BG003', 'title': 'Oxycodone HCL IR Fixed Dose 10 mg', 'description': 'oxycodone 10mg taken by mouth every 4-6 hours for 3 days'}, {'id': 'BG004', 'title': 'Placebo Fixed Dose', 'description': 'Matching placebo taken by mouth every 4-6 hours for 3 days'}, {'id': 'BG005', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '62.2', 'spread': '12.20', 'groupId': 'BG000'}, {'value': '62.8', 'spread': '9.24', 'groupId': 'BG001'}, {'value': '63.3', 'spread': '10.3', 'groupId': 'BG002'}, {'value': '61.3', 'spread': '12.39', 'groupId': 'BG003'}, {'value': '64.0', 'spread': '11.23', 'groupId': 'BG004'}, {'value': '62.7', 'spread': '11.11', 'groupId': 'BG005'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '41', 'groupId': 'BG002'}, {'value': '41', 'groupId': 'BG003'}, {'value': '44', 'groupId': 'BG004'}, {'value': '197', 'groupId': 'BG005'}]}, {'title': 'Male', 'measurements': [{'value': '38', 'groupId': 'BG000'}, {'value': '39', 'groupId': 'BG001'}, {'value': '34', 'groupId': 'BG002'}, {'value': '26', 'groupId': 'BG003'}, {'value': '31', 'groupId': 'BG004'}, {'value': '168', 'groupId': 'BG005'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 367}}, 'statusModule': {'whyStopped': 'Slow enrollment', 'overallStatus': 'TERMINATED', 'startDateStruct': {'date': '2006-10'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-04', 'completionDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2014-04-03', 'studyFirstSubmitDate': '2006-08-11', 'resultsFirstSubmitDate': '2008-12-19', 'studyFirstSubmitQcDate': '2006-08-11', 'lastUpdatePostDateStruct': {'date': '2014-04-21', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2009-05-14', 'studyFirstPostDateStruct': {'date': '2006-08-15', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2009-07-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2007-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Sum of Pain Intensity Difference Over 48 Hours (SPID48)', 'timeFrame': '48 hours', 'description': 'The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (48 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.'}], 'secondaryOutcomes': [{'measure': 'Time to First Rescue Pain Medication.', 'timeFrame': '3 days'}, {'measure': 'The SPID at 12, 24, and 72 Hours Relative to First Dose.', 'timeFrame': '3 days', 'description': 'The SPID score incorporates the cumulative analgesic effects of tapentadol IR on pain intensity over an extended period (12 to 72 hours) allowing for an evaluation of multiple doses of drug, even when dosing frequency may vary. Scoring is derived from the Numerical Rating Scale (NRS) from 0 = No pain to 11 = Pain as bad as you can imagine.'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'keywords': ['Arthralgia', 'Pain', 'Pain Assessment', 'Hip Replacement', 'Tapentadol'], 'conditions': ['Arthroplasty']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=61&filename=CR011221_CSR.pdf', 'label': 'A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to test in patients who have had hip replacement surgery the effectiveness (level of pain control) and the safety of 3 different dose levels of CG5503 compared with placebo and with 10-mg oxycodone during the 72-hour double-blind period and to assess the safety of the drug for 9 days after patients completed the double blind period.', 'detailedDescription': 'Patients undergoing hip replacement often experience moderate to severe acute pain post-surgery. Normally such pain is controlled when patients receive repeated doses of opioid analgesics. However, opioid therapy is commonly associated with side effects such as nausea, vomiting, sedation, constipation, addiction, tolerance, and respiratory depression. CG5503, a newly synthesized drug also acts as a centrally acting pain reliever but has a dual mode of action. The aim of this study is to investigate the effectiveness (level of pain control) and safety (side effects) of 3 dose levels of CG5503, in an immediate release, (IR) formulation, compared with no drug (placebo) or one dose level of oxycodone (an opioid commonly used to treat post-surgical pain). This study is a randomized, double-blind (neither investigator nor patient will know which treatment was received), active- and placebo-controlled, parallel-group, multicenter study to evaluate the treatment of acute pain from hip replacement surgery. The study will include a blinded 72 hour in-patient phase immediately following hip replacement surgery, during which patients will be treated with either 50-, 75-, or 100-mg CG5503 base IR, a placebo, or 10-mg oxycodone, and pain relief will be periodically assessed. Following this phase, patients wishing to continue treatment with CG5503 IR may enter an outpatient voluntary nonrandomized, open-label extension phase for 9 days during which they will receive 50- or 100-mg CG5503 IR. Assessments of pain relief include the pain intensity numeric rating scale (PI), pain relief numeric rating scale (PAR) and patient global impression of change scale (PGIC). Safety evaluations include monitoring of adverse events, physical examinations, and clinical laboratory tests. Venous blood samples will be collected for the determination of serum concentrations of CG5503 and oxycodone. The null hypothesis for the study is that efficacy results for all CG5503 IR dosage groups are equal to placebo based on the mean sum of pain intensity difference at 48 hours. The alternative study hypothesis is that at least 1 dose strength of CG5503 will be different from placebo in controlling pain at 48 hours. CG5503 base IR 50, or 75, or 100 mg, or oxycodone 10 mg, or placebo, 1 capsule taken by mouth every 4 to 6 hours during the 72 hour postsurgery phase of the study (one extra dose is allowed, if needed for pain); and CG5503, 50 mg base capsules, 1 to 2 tablets taken by mouth every 4 to 6 hours for up to 9 days during the open label portion of the study. All doses of study treatment will be taken with approximately 120 mL of water with or with food.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '80 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Scheduled to undergo standard primary (first-time) one-sided total hip replacement surgery due to degenerative joint disease (arthritis), not due to some inflammatory process, (eg. infection)\n* Baseline pain intensity \\>= 4 on an 11-point (0 to 10) Pain Intensity rating scale, rated within 30 minutes before randomization\n* Women must be postmenopausal, surgically sterile, or practicing or agree to practice an effective method of birth control throughout the study\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if they have a history of seizure disorder or epilepsy\n* history of malignancy within the past 2 years before starting the study\n* history of alcohol or drug abuse\n* evidence of active infections that may spread to other areas of the body\n* clinical laboratory values reflecting moderate or severe kidney insufficiency\n* currently treated with anticonvulsants, monoamine oxidase inhibitors, tricyclic antidepressants, neuroleptics, or selective norepinephrine reuptake inhibitor (SNRI), (selective serotonin reuptake inhibitor \\[SSRI\\] treatments are allowed if taken for at least 30 days before the screening period of the study at an unchanged dose)'}, 'identificationModule': {'nctId': 'NCT00364533', 'briefTitle': 'A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety', 'organization': {'class': 'INDUSTRY', 'fullName': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'}, 'officialTitle': 'A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Multiple Doses of CG5503 Immediate Release Formulation in the Treatment of Acute Pain From Total Hip Replacement Surgery Followed by a Voluntary Open-Label Extension', 'orgStudyIdInfo': {'id': 'CR011221'}, 'secondaryIdInfos': [{'id': 'R331333PAI3001', 'type': 'OTHER', 'domain': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'}, {'id': 'KF5503/31', 'type': 'OTHER', 'domain': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': '003', 'description': 'Placebo Fixed Dose Matching placebo for 3 days', 'interventionNames': ['Drug: Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': '002', 'description': 'Oxycodone HCL IR Fixed Dose 10 mg BID for 3 days', 'interventionNames': ['Drug: Oxycodone HCL IR']}, {'type': 'EXPERIMENTAL', 'label': '001', 'description': 'Tapentadol IR (CG5503) Fixed Dose 50, 75, \\& 100 mg BID for 3 days', 'interventionNames': ['Drug: Tapentadol IR (CG5503)']}, {'type': 'OTHER', 'label': '004', 'description': 'Tapentadol IR (CG5503) Flexible Dose q4-6 hr Tapentadol IR 50 \\& 100 mg BID for 9 days', 'interventionNames': ['Drug: Tapentadol IR (CG5503)']}], 'interventions': [{'name': 'Tapentadol IR (CG5503)', 'type': 'DRUG', 'description': 'Fixed Dose 50, 75, \\& 100 mg BID for 3 days', 'armGroupLabels': ['001']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'Fixed Dose Matching placebo for 3 days', 'armGroupLabels': ['003']}, {'name': 'Oxycodone HCL IR', 'type': 'DRUG', 'description': 'Fixed Dose 10 mg BID for 3 days', 'armGroupLabels': ['002']}, {'name': 'Tapentadol IR (CG5503)', 'type': 'DRUG', 'description': 'Flexible Dose q4-6 hr Tapentadol IR 50 \\& 100 mg BID for 9 days', 'armGroupLabels': ['004']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'city': 'Mobile', 'state': 'Alabama', 'country': 'United States', 'geoPoint': {'lat': 30.69436, 'lon': -88.04305}}, {'city': 'Sheffield', 'state': 'Alabama', 'country': 'United States', 'geoPoint': {'lat': 34.76509, 'lon': -87.69864}}, {'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'city': 'Fort Smith', 'state': 'Arkansas', 'country': 'United States', 'geoPoint': {'lat': 35.38592, 'lon': -94.39855}}, {'city': 'Little Rock', 'state': 'Arkansas', 'country': 'United States', 'geoPoint': {'lat': 34.74648, 'lon': -92.28959}}, {'city': 'Anaheim', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.83529, 'lon': -117.9145}}, {'city': 'Arcadia', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 34.13973, 'lon': -118.03534}}, {'city': 'Glendale', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 34.14251, 'lon': -118.25508}}, {'city': 'Laguna Hills', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 33.61252, 'lon': -117.71283}}, {'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'city': 'San Francisco', 'state': 'California', 'country': 'United States', 'geoPoint': {'lat': 37.77493, 'lon': -122.41942}}, {'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'city': 'Farmington', 'state': 'Connecticut', 'country': 'United States', 'geoPoint': {'lat': 41.71982, 'lon': -72.83204}}, {'city': 'Boynton Beach', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.52535, 'lon': -80.06643}}, {'city': 'DeLand', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 29.02832, 'lon': -81.30312}}, {'city': 'Fort Lauderdale', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.12231, 'lon': -80.14338}}, {'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'city': 'Plantation', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.13421, 'lon': -80.23184}}, {'city': 'Port Orange', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 29.13832, 'lon': -80.99561}}, {'city': 'Tamarac', 'state': 'Florida', 'country': 'United States', 'geoPoint': {'lat': 26.21286, 'lon': -80.24977}}, {'city': 'Decatur', 'state': 'Georgia', 'country': 'United States', 'geoPoint': {'lat': 33.77483, 'lon': -84.29631}}, {'city': 'Chicago', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 41.85003, 'lon': -87.65005}}, {'city': 'Peoria', 'state': 'Illinois', 'country': 'United States', 'geoPoint': {'lat': 40.69365, 'lon': -89.58899}}, {'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'city': 'Topeka', 'state': 'Kansas', 'country': 'United States', 'geoPoint': {'lat': 39.04833, 'lon': -95.67804}}, {'city': 'Baltimore', 'state': 'Maryland', 'country': 'United States', 'geoPoint': {'lat': 39.29038, 'lon': -76.61219}}, {'city': 'Boston', 'state': 'Massachusetts', 'country': 'United States', 'geoPoint': {'lat': 42.35843, 'lon': -71.05977}}, {'city': 'Royal Oak', 'state': 'Michigan', 'country': 'United States', 'geoPoint': {'lat': 42.48948, 'lon': -83.14465}}, {'city': 'Albany', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 42.65258, 'lon': -73.75623}}, {'city': 'Mineola', 'state': 'New York', 'country': 'United States', 'geoPoint': {'lat': 40.74927, 'lon': -73.64068}}, {'city': 'Charlotte', 'state': 'North Carolina', 'country': 'United States', 'geoPoint': {'lat': 35.22709, 'lon': -80.84313}}, {'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'city': 'Sewickley', 'state': 'Pennsylvania', 'country': 'United States', 'geoPoint': {'lat': 40.53646, 'lon': -80.1845}}, {'city': 'Nashville', 'state': 'Tennessee', 'country': 'United States', 'geoPoint': {'lat': 36.16589, 'lon': -86.78444}}, {'city': 'Austin', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 30.26715, 'lon': -97.74306}}, {'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'city': 'Grapevine', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 32.93429, 'lon': -97.07807}}, {'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'city': 'Lubbock', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 33.57786, 'lon': -101.85517}}, {'city': 'Plano', 'state': 'Texas', 'country': 'United States', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'city': 'Murray', 'state': 'Utah', 'country': 'United States', 'geoPoint': {'lat': 40.66689, 'lon': -111.88799}}, {'city': 'Weston', 'state': 'Wisconsin', 'country': 'United States', 'geoPoint': {'lat': 44.8908, 'lon': -89.54762}}, {'city': 'Aalst', 'country': 'Belgium', 'geoPoint': {'lat': 50.93604, 'lon': 4.0355}}, {'city': 'Genk', 'country': 'Belgium', 'geoPoint': {'lat': 50.965, 'lon': 5.50082}}, {'city': 'Ghent', 'country': 'Belgium', 'geoPoint': {'lat': 51.05, 'lon': 3.71667}}, {'city': 'Leuven', 'country': 'Belgium', 'geoPoint': {'lat': 50.87959, 'lon': 4.70093}}, {'city': 'Halifax', 'state': 'Nova Scotia', 'country': 'Canada', 'geoPoint': {'lat': 44.64269, 'lon': -63.57688}}, {'city': 'Burlington', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.38621, 'lon': -79.83713}}, {'city': 'Newmarket', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 44.05011, 'lon': -79.46631}}, {'city': 'Oshawa', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.90012, 'lon': -78.84957}}, {'city': 'Scarborough Village', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.73899, 'lon': -79.22124}}, {'city': 'Thunder Bay', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 48.38202, 'lon': -89.25018}}, {'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'city': 'London', 'country': 'Canada', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'city': 'Helsinki', 'country': 'Finland', 'geoPoint': {'lat': 60.16952, 'lon': 24.93545}}, {'city': 'Tampere', 'country': 'Finland', 'geoPoint': {'lat': 61.49911, 'lon': 23.78712}}, {'city': 'Turku', 'country': 'Finland', 'geoPoint': {'lat': 60.45148, 'lon': 22.26869}}, {'city': 'Hamilton', 'country': 'New Zealand', 'geoPoint': {'lat': -37.78333, 'lon': 175.28333}}, {'city': 'Cadiz', 'country': 'Spain', 'geoPoint': {'lat': 36.52672, 'lon': -6.2891}}, {'city': 'Madrid', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'city': 'Valencia', 'country': 'Spain', 'geoPoint': {'lat': 39.47391, 'lon': -0.37966}}, {'city': 'Borås', 'country': 'Sweden', 'geoPoint': {'lat': 57.72101, 'lon': 12.9401}}, {'city': 'Hässleholm', 'country': 'Sweden', 'geoPoint': {'lat': 56.15905, 'lon': 13.76638}}, {'city': 'Örebro', 'country': 'Sweden', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'city': 'Uppsala', 'country': 'Sweden', 'geoPoint': {'lat': 59.85882, 'lon': 17.63889}}, {'city': 'Aberdeen', 'country': 'United Kingdom', 'geoPoint': {'lat': 57.14369, 'lon': -2.09814}}, {'city': 'Birmingham', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.48142, 'lon': -1.89983}}, {'city': 'Edinburgh', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'city': 'Great Yarmouth', 'country': 'United Kingdom', 'geoPoint': {'lat': 52.60831, 'lon': 1.73052}}, {'city': 'London', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'city': 'Middlesex', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.53174, 'lon': -0.26856}}, {'city': 'Sheffield', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.38297, 'lon': -1.4659}}, {'city': 'Wigan', 'country': 'United Kingdom', 'geoPoint': {'lat': 53.54296, 'lon': -2.63706}}], 'overallOfficials': [{'name': 'Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Johnson & Johnson Pharmaceutical Research & Development, L.L.C.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Grünenthal GmbH', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'SPONSOR'}}}}